WO2006119168A3 - Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors - Google Patents
Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors Download PDFInfo
- Publication number
- WO2006119168A3 WO2006119168A3 PCT/US2006/016590 US2006016590W WO2006119168A3 WO 2006119168 A3 WO2006119168 A3 WO 2006119168A3 US 2006016590 W US2006016590 W US 2006016590W WO 2006119168 A3 WO2006119168 A3 WO 2006119168A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analogs
- cox
- carotenoids
- derivatives
- selective inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06758837A EP1890729A2 (en) | 2005-05-02 | 2006-05-02 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors |
CA002613169A CA2613169A1 (en) | 2005-05-02 | 2006-05-02 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67595905P | 2005-05-02 | 2005-05-02 | |
US60/675,959 | 2005-05-02 | ||
US69971705P | 2005-07-15 | 2005-07-15 | |
US60/699,717 | 2005-07-15 | ||
US71845005P | 2005-09-19 | 2005-09-19 | |
US60/718,450 | 2005-09-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006119168A2 WO2006119168A2 (en) | 2006-11-09 |
WO2006119168A3 true WO2006119168A3 (en) | 2007-01-25 |
Family
ID=37308576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/016590 WO2006119168A2 (en) | 2005-05-02 | 2006-05-02 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1890729A2 (en) |
CA (1) | CA2613169A1 (en) |
WO (1) | WO2006119168A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2610502A1 (en) * | 2005-03-29 | 2006-10-05 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
US20070238793A1 (en) * | 2005-12-07 | 2007-10-11 | Lockwood Samuel F | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status |
WO2008106606A2 (en) * | 2007-02-28 | 2008-09-04 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives in the treatment of prostate cancer |
US7805004B2 (en) * | 2007-02-28 | 2010-09-28 | Microsoft Corporation | Radical set determination for HMM based east asian character recognition |
SG11201609405VA (en) * | 2014-05-20 | 2016-12-29 | Fuji Chem Ind Co Ltd | Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061572A2 (en) * | 2002-01-16 | 2003-07-31 | David Haines | Anti-inflammatory formulations |
WO2005002542A2 (en) * | 2003-03-03 | 2005-01-13 | Elan Pharma International Ltd. | Nanoparticulate meloxican formulations |
WO2005009422A1 (en) * | 2003-07-16 | 2005-02-03 | Natural Alternatives International, Inc. | Anti-inflammatory formulations |
-
2006
- 2006-05-02 EP EP06758837A patent/EP1890729A2/en not_active Withdrawn
- 2006-05-02 WO PCT/US2006/016590 patent/WO2006119168A2/en active Application Filing
- 2006-05-02 CA CA002613169A patent/CA2613169A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061572A2 (en) * | 2002-01-16 | 2003-07-31 | David Haines | Anti-inflammatory formulations |
WO2005002542A2 (en) * | 2003-03-03 | 2005-01-13 | Elan Pharma International Ltd. | Nanoparticulate meloxican formulations |
WO2005009422A1 (en) * | 2003-07-16 | 2005-02-03 | Natural Alternatives International, Inc. | Anti-inflammatory formulations |
Non-Patent Citations (1)
Title |
---|
MASON R PRESTON ET AL: "Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2006, vol. 47 Suppl 1, 2006, pages S7 - 14, XP009075108, ISSN: 0160-2446 * |
Also Published As
Publication number | Publication date |
---|---|
EP1890729A2 (en) | 2008-02-27 |
WO2006119168A2 (en) | 2006-11-09 |
CA2613169A1 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009221765B2 (en) | Compositions and methods for mucositis and oncology therapies | |
WO2006105214A3 (en) | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof | |
CA2646131C (en) | Compositions and methods for ameliorating cachexia | |
WO2006119168A3 (en) | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors | |
CR7654A (en) | A COMBINATION OF AZELATINE AND STEROIDS | |
JP7370966B2 (en) | Methods and improved neuroprotective compositions for treating neurological conditions | |
BR0307540A (en) | Pharmaceutical preparation in film or lamina form for administering active substances, use of the pharmaceutical preparation and method for the oral administration of bitter-tasting pharmaceutically active substance (s) | |
Yan et al. | Vitamin supplements in type 2 diabetes mellitus management: A review | |
KR102602826B1 (en) | Biologically-active tomato composition having reduced amount of lycopene | |
WO2006079900A8 (en) | Injection device for administering a medication liquid | |
AR048318A1 (en) | ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA | |
BRPI0617693A2 (en) | azithromycin for the treatment of granulomatous rosacea | |
Wang et al. | Combination of broccoli sprout extract and zinc provides better protection against intermittent hypoxia‐induced cardiomyopathy than monotherapy in mice | |
RU2003122060A (en) | CAROTINOIDS AS ANTIHYPERTENSIVE AGENTS | |
Hu et al. | Secoisolariciresinol diglycoside, a flaxseed lignan, exerts analgesic effects in a mouse model of type 1 diabetes: Engagement of antioxidant mechanism | |
KR101891360B1 (en) | Medicinal agent for prevention and/or treatment of hepatocellular carcinoma | |
Torge et al. | Polycystic ovary syndrome in adolescence: New therapeutic approach with inositol and alpha-lipoic acid | |
Khavinson et al. | 35-year experience in research of peptide regulation of aging | |
ZA202211148B (en) | Use of tetrandrine in combination with all-trans retinoic acid in preparation of medicament for treating pneumoconiosis | |
WO2009037584A3 (en) | Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease | |
Ruocco | Pemphigus vulgaris V. Ruocco, and S. Brenner | |
Signifor | t ACTINIC KERATOSIS | |
Tseng et al. | Fixed-Dose Combination Therapy of Rosiglitazone and Metformin for Drug-Naïve Type 2 Diabetes Mellitus | |
WO2014168191A1 (en) | Prophylactic and/or therapeutic agent for hepatocellular carcinoma | |
Mucalo et al. | Effect of American ginseng on arterial stiffness in subjects with well-controlled type-2 diabetes and hypertension. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006758837 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
ENP | Entry into the national phase |
Ref document number: 2613169 Country of ref document: CA |